National Survey Identifies Significant Growth in Receptor Agonist Utilization for Weight Management
Recent national survey data shows that 11 percent of adults currently use a glucagon-like peptide-1 receptor agonist medication for…
Recent national survey data shows that 11 percent of adults currently use a glucagon-like peptide-1 receptor agonist medication for…
Nestle is changing some product formulations to meet the taste needs of patients using GLP-1 receptor agonists. Marketing chief…
Urinary incontinence affects a significant number of women who are obese and have type 2 diabetes. Extra body fat…
Patients managing both atrial fibrillation and type 2 diabetes face increased cardiovascular risks. These individuals have higher rates of…
The oral form of semaglutide is the first widely available glucagon-like peptide-1 receptor agonist that does not require an…
An investigational drug called apitegromab reduces lean muscle loss in patients using GLP-1 receptor agonists. Researchers published these findings…
Glucagon-like peptide-1 receptor agonists have significantly changed how we manage obesity and type 2 diabetes. Medications like Ozempic, Wegovy,…
Glucagon-like peptide-1 receptor agonists and tirzepatide have changed how we manage obesity and type 2 diabetes. As a result,…
Clinicians and patients often come across the term GLP-3 when discussing new obesity treatments. This term does not have…
GLP-1 receptor agonists have changed weight management and blood sugar control for millions of patients. Most clinical focus tends…